Operation Access Now enables pharmaceutical manufacturers to launch direct‑to‑patient programs within 21 days

BlinkRx, the nation's leading prescription lifecycle management platform, today announced the launch of Operation Access Now, a rapid deployment initiative that enables pharmaceutical manufacturers to build and launch direct-to-patient (DTP) and direct‑to‑business (DTB) channels that expand medication access and deliver pricing transparency in as little as 21 days.

This program comes at a moment of growing urgency across the life sciences industry. As traditional access models struggle to meet patient and provider expectations, leading brands are turning to faster, more scalable approaches.

BlinkRx’s national infrastructure already supports millions of patients across all 50 states. The platform’s patient-centric design removes every barrier for patients to start and stay on therapy and delivers significant lift for brands: on average, 52% more patient starts and 41% more fills per patient.

With Operation Access Now, the initiative enables:

• Rapid Stand‑Up: DTP programs that can be operational in as little as 21 days, thanks to BlinkRx’s turnkey platform and flexible rules engine.
• Future-Proof: A modular platform that allows pharmaceutical manufacturers to start with a DTP solution and expand into future capabilities as needs and regulations change. For example, the platform can be deployed for DTB models, and can service both cashpay and insurance patients.
• Scale: Unique automation capabilities that enable pharmaceutical manufacturers to effortlessly scale based on patient demand and adoption.

Legacy DTP solutions, such as copay cards and standalone cash pharmacies, are often costly, inefficient, and prone to patient and physician frustration- causing delays in access, misuse, and poor experiences. BlinkRx's platform addresses these ecosystem issues while ensuring strict regulatory compliance.

“Operation Access Now is about removing every barrier between manufacturers and the patients who need their therapies,” said Geoffrey Chaiken, Co‑Founder and CEO of BlinkRx. “We’re prepared to enable manufacturers to deploy DTP programs and deliver the speed, scale, and flexibility the market demands.”

About BlinkRx

BlinkRx is a Prescription Lifecycle Management Platform that allows the most innovative Life Sciences companies to design every aspect of the prescription journey to unlock branded medication affordability and access for all Americans. Learn more at www.blinkrx.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250807070685/en/